AFC-HD AMS Life Science Co

AFC-HD AMS Life Science Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of AFC-HD AMS Life Science Co (2927.T) as of Nov 4, 2026 is -60.59 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -120.95 % — a change of -49.90% (higher).

FCF Conversion

-60.59 %

YoY

-49.90%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of AFC-HD AMS Life Science Co is 2026 -60.59 % . FCF Conversion Rate (FCF/EBITDA) of AFC-HD AMS Life Science Co was 2025 -120.95 % . It decreases by -49.90% higher compared to the previous year.

The AFC-HD AMS Life Science Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
74.70 JPY
Jan 1, 2020
135.62 JPY
Jan 1, 2021
139.79 JPY
Jan 1, 2022
72.68 JPY
Jan 1, 2023
-97.45 JPY
Jan 1, 2024
-149.09 JPY
Jan 1, 2025
-120.95 JPY
Jan 1, 2026
-60.59 JPY
The AFC-HD AMS Life Science Co FCF Conversion history
YEARFCF ConversionYoY
-60.59 %-49.90%
-120.95 %-18.88%
-149.09 %+53.00%
-97.45 %-234.08%
72.68 %-48.01%
139.79 %+3.07%
135.62 %+81.55%
74.70 %-18.14%
91.26 %-230.29%
-70.04 %-149.62%
141.17 %+42.66%
98.96 %-57.81%
234.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AFC-HD AMS Life Science Co Stock analysis

What does AFC-HD AMS Life Science Co do? AFC-HD AMS Life Science Co., Ltd. generates revenue through its Healthcare segment, which produces and sells health foods, cosmetics, and OEM services for other brands. The Pharmaceutical segment manufactures and sells ethical drugs, over-the-counter drugs, and generic medicines. The company also manages restaurants via a subsidiary, contributing to its diversified income streams. Customers include businesses seeking OEM partnerships and consumers purchasing health and pharmaceutical products. The firm's products are sold under its own brand and through OEM agreements, targeting both individual consumers and corporate clients. The Healthcare segment focuses on wellness products, while the Pharmaceutical segment caters to medical needs with prescription and non-prescription drugs. The restaurant management subsidiary provides additional revenue from food service operations. Revenue is derived from the sale of health foods, cosmetics, Chinese medicine medicines, general medicines, and healthcare products within the Healthcare segment. The Pharmaceutical segment's income comes from ethical drugs, over-the-counter drugs, and generic medicines. The restaurant subsidiary's operations further support the company's financial structure through food service sales. AFC-HD AMS Life Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AFC-HD AMS Life Science Co stock

FCF Conversion Rate (FCF/EBITDA) of AFC-HD AMS Life Science Co is -60.59 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of AFC-HD AMS Life Science Co changed from -120.95 % to -60.59 %, representing a -49.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) AFC-HD AMS Life Science Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s AFC-HD AMS Life Science Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — AFC-HD AMS Life Science Co

All Key Metrics — AFC-HD AMS Life Science Co